Adverse Reactions and Pathogen Safety of Intravenous Immunoglobulin

By  

Current Drug Safety, Vol. 2, Iss. 1, 2007-01 ,pp. : 9-18

Bentham Science Publishers

Access to resources Recommend Favorite

An open, prospective trial investigating the pharmacokinetics and safety, and the tolerability of escalating infusion rates of a 10% human normal immunoglobulin for intravenous infusion (IVIg), BT090, in patients with primary immunodeficiency disease

By  

VOX SANGUINIS, Vol. 109, Iss. 3, 2015-10 ,pp. : 248-256

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical Efficacy of Intravenous Immunoglobulin for Patients with MPO-ANCA-Associated Rapidly Progressive Glomerulonephritis

By  

Nephron Clin Pract, Vol. 102, Iss. 1, 2005-09 ,pp. : c35-c42

Karger

Access to resources Recommend Favorite

Increased hemolysis after administering intravenous immunoglobulin to a neonate with erythroblastosis fetalis due to Rh hemolytic disease

By  

TRANSFUSION, Vol. 55, Iss. 6, 2015-06 ,pp. : 1365-1366

John Wiley & Sons Inc

Access to resources Recommend Favorite

EFFECT OF INTRAVENOUS IMMUNOGLOBULIN IN PATIENTS WITH POST-POLIO SYNDROME – AN UNCONTROLLED PILOT STUDY

By Kaponides Georgios   Gonzalez Henrik   Olsson Tomas   Borg Kristian  

Journal of Rehabilitation Medicine, Vol. 38, Iss. 2, 2006-03 ,pp. : 138-140

Medical Journals Limited

Access to resources Recommend Favorite